CVS Health recorded $67.1 billion revenues in Q3 2020 results, up 3.5% from the prior year, according to the company’s press release. Quarterly revenue growth reflects planned investments, holistic and innovative solutions that meet the needs of the customers. 

  • 2020 Full Year Guidance
    • CVS Health raises GAAP diluted earnings per share (EPS) range from $5.16-5.29 to $5.60-5.70.
    • The company raises adjusted EPS guidance range from $7.14-7.27 to $7.35-7.45.
    • The company raises cash flow from operations guidance range from $11.0-11.5 billion to $12.75-13.25 billion.
  • Q3 and Year-to-date Highlights 
    • Adjusted EPS was $1.66, down from $1.84 in the comparable quarter of 2019.
    • Adjusted operating income was $3.6 billion, down from $3.95 billion in the comparable quarter of 2019.
    • Net income was $1.22 billion, down from $1.53 billion, in the comparable quarter of 2019.
    • The company generated year-to-date cash flow from operations amounting to $12.3 billion.
    • The company has doubled the number of test sites to more than 4,000 CVS Pharmacy locations countrywide. 
    • CVS Health has been selected to administer vaccines to long-term care facilities.
    • The consumer-driven health care model is increasing access to products and services.

CVS Health stock is currently gaining. CVS: NYSE is up on premarket 2.59%